Holen Sie sich die Stockscreener-App
103.00
1.40%
-1.46
Handel nachbörslich:
103.00
Schlusskurs vom Vortag:
$104.46
Offen:
$103.55
24-Stunden-Volumen:
661.18K
Relative Volume:
0.75
Marktkapitalisierung:
$5.05B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-15.77
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-0.51%
1M Leistung:
-18.76%
6M Leistung:
+12.57%
1J Leistung:
+51.69%
1-Tages-Spanne:
$101.58
$104.17
1-Wochen-Bereich:
$101.32
$105.66
52-Wochen-Spanne:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
103.00 | 5.05B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Leerink Partnrs Has Bearish Outlook for AXSM Q1 Earnings - MarketBeat
Russell Investments Group Ltd. Boosts Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Leerink Partnrs Brokers Increase Earnings Estimates for AXSM - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Holdings Lowered by Affinity Asset Advisors LLC - MarketBeat
Axsome slips as late-stage trial for depression therapy fails - MSN
1492 Capital Management LLC Purchases New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
LPL Financial LLC Buys 7,837 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Kennedy Capital Management LLC Raises Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
91,649 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Granite Investment Partners LLC - MarketBeat
Invesco Ltd. Increases Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Reduced by Alliancebernstein L.P. - MarketBeat
XTX Topco Ltd Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Trexquant Investment LP Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now - The Globe and Mail
Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment? - simplywall.st
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm - Kilgore News Herald
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO - GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office Today - GlobeNewswire Inc.
Zacks Research Analysts Decrease Earnings Estimates for AXSM - MarketBeat
What is Zacks Research's Forecast for AXSM FY2025 Earnings? - MarketBeat
American Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 6.9%What's Next? - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Raised by ADAR1 Capital Management LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Franklin Resources Inc. Purchases 21,756 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands - Bluefield Daily Telegraph
Attention Long-Term Shareholders of Axsome Therapeutics, - GlobeNewswire
Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
Axsome (AXSM) Reports Positive Phase 3 Results for ADHD Treatmen - GuruFocus
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy - Yahoo Finance
Norges Bank Purchases Shares of 403,026 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Wellington Management Group LLP Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
AAN 2025: Axsome Therapeutics’ treatment for Alzheimer’s agitation shows promise - Yahoo
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to C - GuruFocus
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics - Bluefield Daily Telegraph
ALERT: Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - The Manila Times
Axsome Earnings Alert: CNS Drug Leader Sets Q1 2025 Results Date - Stock Titan
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):